Methylprednisolone sodium succinate (U-9088; 6α-Methylprednisolone 21-hemisuccinate sodium) is a water-soluble ester of Methylprednisolone (also known as NSC-19987) which is a synthetic and potent glucocorticoid receptor agonist, used to achieve prompt suppression of inflammation. It is used for cardiac, allergic, and hypoxic emergencies. Methylprednisolone sodium succinate has slightly longer half-life than that of Prednisolone.
Physicochemical Properties
| Molecular Formula | C26H33NAO8 |
| Molecular Weight | 496.53 |
| Exact Mass | 496.207 |
| Elemental Analysis | C, 62.89; H, 6.70; Na, 4.63; O, 25.78 |
| CAS # | 2375-03-3 |
| Related CAS # | Methylprednisolone succinate;2921-57-5 |
| PubChem CID | 23680530 |
| Appearance | White to off-white solid powder |
| Boiling Point | 689.6ºC at 760mmHg |
| Flash Point | 230.7ºC |
| LogP | 0.884 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 35 |
| Complexity | 988 |
| Defined Atom Stereocenter Count | 8 |
| SMILES | C[C@@]12[C@](C(COC(CCC([O-])=O)=O)=O)(O)CC[C@@]1([H])[C@]3([H])C[C@H](C)C4=CC(C=C[C@]4(C)[C@@]3([H])[C@@H](O)C2)=O.[Na+] |
| InChi Key | FQISKWAFAHGMGT-SGJOWKDISA-M |
| InChi Code | InChI=1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/q+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-/m0./s1 |
| Chemical Name | Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-6-alpha-methyl-, 21- (hydrogen succinate), monosodium salt |
| Synonyms | Methylprednisolone sodium succinate; U 9088; U-9088; U9088 |
| HS Tariff Code | 2934.99.03.00 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Methylprednisolone sodium succinate reduces BBB disruption and inflammation in a model mouse of intracranial haemorrhage. Brain Res Bull. 2016;127:226-233. [2]. Li LL, Huang LL, Miu SJ, Zhang H. [Local combined with systemic glucocorticoid treatment of young and middle-aged patients with severe and profound hearing loss]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Apr;32(7):533-536. d |
| Additional Infomation |
Methylprednisolone sodium succinate is a corticosteroid hormone. Methylprednisolone Sodium Succinate is the sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved. A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies. See also: Methylprednisolone (has active moiety). |
Solubility Data
| Solubility (In Vitro) |
H2O : ~50 mg/mL ~(100.70 mM) Ethanol : ~100 mg/mL DMSO :25~100 mg/mL (50.35~201.39 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (4.19 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0140 mL | 10.0699 mL | 20.1398 mL | |
| 5 mM | 0.4028 mL | 2.0140 mL | 4.0280 mL | |
| 10 mM | 0.2014 mL | 1.0070 mL | 2.0140 mL |